| Financial Information Relating to Reportable Segments |
The Company has two
reportable segments based on the nature of products (biotechnology
and hematology). Following is financial information relating to the
Company’s reportable segments (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended
March 31, |
|
|
Nine Months Ended
March 31, |
|
| |
2013 |
|
|
2012 |
|
|
2013 |
|
|
2012 |
|
|
External sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
75,285 |
|
|
$ |
78,180 |
|
|
$ |
214,416 |
|
|
$ |
220,291 |
|
|
Hematology
|
|
|
5,707 |
|
|
|
5,441 |
|
|
|
16,684 |
|
|
|
15,588 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated net
sales
|
|
$ |
80,992 |
|
|
$ |
83,621 |
|
|
$ |
231,100 |
|
|
$ |
235,879 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before income
taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
43,246 |
|
|
$ |
45,442 |
|
|
$ |
117,123 |
|
|
$ |
123,304 |
|
|
Hematology
|
|
|
2,247 |
|
|
|
2,037 |
|
|
|
6,498 |
|
|
|
5,636 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment earnings before
income taxes
|
|
|
45,493 |
|
|
|
47,479 |
|
|
|
123,621 |
|
|
|
128,940 |
|
|
Unallocated corporate
expenses and equity method investee losses
|
|
|
(1,027 |
) |
|
|
(4,274 |
) |
|
|
(3,723 |
) |
|
|
(7,362 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated earnings before
income taxes
|
|
$ |
44,466 |
|
|
$ |
43,205 |
|
|
$ |
119,898 |
|
|
$ |
121,578 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|